Haduvio™
We are developing the investigational therapy Haduvio™ (nalbuphine ER) unlocking new market opportunities and the potential to significantly improve the quality of life of patients suffering from the serious symptoms associated with chronic neurologically mediated conditions.
Passionate about Progress
Backed by expert scientific and medical advisors and dedicated to our investors, the Trevi leadership team is highly engaged and experienced in life science clinical development, successful commercialization, and building companies of exceptional value.
Passionate about Progress
Backed by expert scientific and medical advisors and dedicated to our investors, the Trevi leadership team is highly engaged and experienced in life science clinical development, successful commercialization, and building companies of exceptional value.
A New Hope for Patients with Chronic and Serious Neurologically Mediated Conditions
We are developing the investigational therapy Haduvio™ as an oral treatment for a broad range of chronic conditions for which patients have few, if any, treatment options. With its differentiated dual mechanism of action, Haduvio™ has the potential to significantly improve the quality of life of patients.
Committed to Excellence in Pharmaceutical Development and Bringing Solutions to Patients
news
Trevi Therapeutics Announces First Quarter 2021 Financial Results and Business Update
05/13/2021Phase 2b/3 PRISM (Chronic Pruritus in PN) Trial Over 70% Enrolled
Trevi Therapeutics to Report Q1 2021 Financial Results on May 13
05/06/2021Conference Call and Webcast to be Held at 4:30 p.m. ET
